The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach.
Centralized drug procurement is a common practice worldwide to relieve the healthcare burden and promote high-quality development in the pharmaceutical industry. However, scholars have not yet reached an agreement on whether centralized procurement can facilitate the innovation activities of pharmac...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0315811 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555580067512320 |
|---|---|
| author | Fangjun Qiu Shouming Chen Yujia Li Xianjing Wang Mengfei Zhu |
| author_facet | Fangjun Qiu Shouming Chen Yujia Li Xianjing Wang Mengfei Zhu |
| author_sort | Fangjun Qiu |
| collection | DOAJ |
| description | Centralized drug procurement is a common practice worldwide to relieve the healthcare burden and promote high-quality development in the pharmaceutical industry. However, scholars have not yet reached an agreement on whether centralized procurement can facilitate the innovation activities of pharmaceutical firms. China's centralized volume-based procurement (CVBP) implemented in 2018 provides an ideal quasi-natural experiment to evaluate the effect of centralized procurement on the R&D investment of the firms. Drawing data from listed manufacturing firms in China's A-share market (2015-2020), the results from a difference-in-differences analysis with different model specifications indicate that the CVBP significantly promotes the pharmaceutical manufacturing firms' R&D investment. Moreover, the positive effect of the CVBP on R&D investment is stronger in pharmaceutical manufacturing firms with high marketing expenses. A series of robustness tests including the parallel trend test, placebo test, and the PSM-DID analysis show that our findings are solid. This paper advances our understanding of centralized procurement in emerging markets and provides new insights into how governments and pharmaceutical manufacturing firms can strengthen innovation. |
| format | Article |
| id | doaj-art-122778045e8c478f92263dd69dc0792a |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-122778045e8c478f92263dd69dc0792a2025-01-08T05:31:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031581110.1371/journal.pone.0315811The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach.Fangjun QiuShouming ChenYujia LiXianjing WangMengfei ZhuCentralized drug procurement is a common practice worldwide to relieve the healthcare burden and promote high-quality development in the pharmaceutical industry. However, scholars have not yet reached an agreement on whether centralized procurement can facilitate the innovation activities of pharmaceutical firms. China's centralized volume-based procurement (CVBP) implemented in 2018 provides an ideal quasi-natural experiment to evaluate the effect of centralized procurement on the R&D investment of the firms. Drawing data from listed manufacturing firms in China's A-share market (2015-2020), the results from a difference-in-differences analysis with different model specifications indicate that the CVBP significantly promotes the pharmaceutical manufacturing firms' R&D investment. Moreover, the positive effect of the CVBP on R&D investment is stronger in pharmaceutical manufacturing firms with high marketing expenses. A series of robustness tests including the parallel trend test, placebo test, and the PSM-DID analysis show that our findings are solid. This paper advances our understanding of centralized procurement in emerging markets and provides new insights into how governments and pharmaceutical manufacturing firms can strengthen innovation.https://doi.org/10.1371/journal.pone.0315811 |
| spellingShingle | Fangjun Qiu Shouming Chen Yujia Li Xianjing Wang Mengfei Zhu The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach. PLoS ONE |
| title | The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach. |
| title_full | The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach. |
| title_fullStr | The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach. |
| title_full_unstemmed | The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach. |
| title_short | The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach. |
| title_sort | impact of the centralized volume based procurement policy on chinese pharmaceutical manufacturing firms r amp d investment a difference in differences approach |
| url | https://doi.org/10.1371/journal.pone.0315811 |
| work_keys_str_mv | AT fangjunqiu theimpactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT shoumingchen theimpactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT yujiali theimpactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT xianjingwang theimpactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT mengfeizhu theimpactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT fangjunqiu impactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT shoumingchen impactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT yujiali impactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT xianjingwang impactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach AT mengfeizhu impactofthecentralizedvolumebasedprocurementpolicyonchinesepharmaceuticalmanufacturingfirmsrampdinvestmentadifferenceindifferencesapproach |